Inhibitor-resistant HCV NS3 protease
US7208309B2 · kind B2 · utility
8Cited by
7References
6Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Oct 28, 2003 |
| Grant date | Apr 24, 2007 |
| Priority date | — |
| Expiry date | Jan 9, 2025 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12N2770/24222
- WIPO fieldBiotechnology
- WIPO sectorChemistry
Abstract
An inhibitor-resistant HCV NS3 protease is provided which is useful to screen for compounds having therapeutic value against drug resistant HCV strains. In particular, the inhibitor-resistant HCV NS3 protease comprises an amino acid sequence which is mutated in the substrate binding pocket thereof rendering the protease resistant to inhibitor. In a specific aspect of the present invention, at least one of the amino acids at position 155, 156 and 168 of the HCV NS3 protease is mutated to yield an inhibitor-resistant protease.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.